PDVAC Executive summary 2021: HIV monoclonal antibodies Preferred Product Characteristics

Overview

The draft PPC has been developed in consultation with IAVI and an expert working group and was presented to a broad range of stakeholders at a consultation in November 2020. This is the first time that PDVAC is reviewing the draft and presents an opportunity to review the PPC to ensure that it is ready for public consultation. The objectives of the session are to:

• Present the rationale and context for developing WHO PPC guidance for HIV monoclonal antibodies, with a focus on meeting the needs of LMICs, including in the context of other prevention products on the market or on the horizon.
• Evaluate the draft PPC document tables and discuss key characteristics & related issues.
• Gather input on key issues/research priorities to include in an article in a peer reviewed journal, to complement and contextualise the PPC guidance.

The expected outcomes of the session are to:

• Obtain PDVAC recommendations for finalization of the HIV mAb PPC document as a draft for public consultation.
• To identify critical product attributes/characteristics that require further consideration for research and/or evidence to support policy and implementation discussions.